文献速递头颈部肿瘤放疗

在接受调强放射治疗的老年鼻咽癌患者中筛选并验证化疗获益人群:一项大型真实世界研究

Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
PubMed 文献 · Radiat Oncol · 2022-08-08

该真实世界研究纳入2007年4月至2017年12月间1714例老年鼻咽癌患者,采用递归分区分析(RPA)建立风险分层。结果显示EBV DNA≤4000 copies/mL且T1-2为预后良好组,其余为预后不良组;预后不良组中放化疗较单纯放疗显著改善总生存(HR=0.70,95%CI 0.55-0.88,P=0.003)。作者认为EBV DNA<4000 copies/ml且T3-4、EBV DNA≥4000 copies/ml且任何T可能是化疗获益的简单筛选界值,但不适用于>70岁且ACE-27评分>1者。

要点

  • RPA将患者分为预后良好组(EBV DNA≤4000 copies/mL且T1-2)与预后不良组(其余)。
  • 预后不良组中放化疗较单纯放疗显著改善总生存(HR=0.70,95%CI 0.55-0.88,P=0.003)。
  • 诱导化疗+同步放化疗与同步放化疗较单纯放疗显著改善总生存,诱导化疗+放疗未见显著改善。

核心结论

  • 作者认为老年鼻咽癌患者化疗获益的简单筛选界值可能为EBV DNA<4000 copies/ml且T3-4、EBV DNA≥4000 copies/ml且任何T,但不适用于>70岁且ACE-27评分>1者。
  • 诱导化疗+同步放化疗和同步放化疗是有效的化疗形式。

研究设计与样本

  • 真实世界研究,纳入2007年4月至2017年12月间1714例老年鼻咽癌患者。
  • 采用递归分区分析(RPA)生成风险分层结局,并对不同风险组进行个体比较以评估化疗获益。

主要发现

  • 中位随访59.3(0.39-170.09)个月。
  • 预后良好组总生存显著高于训练集(HR=0.309,95%CI 0.184-0.517;P<0.001),并在测试集验证(HR=0.276,95%CI 0.113-0.670;P=0.002)。
  • 预后不良组中放化疗较单纯放疗显著改善总生存(HR=0.70,95%CI 0.55-0.88;P=0.003)。
  • 诱导化疗+同步放化疗与同步放化疗较单纯放疗显著改善总生存(诱导化疗+同步放化疗 vs 单纯放疗:P=0.002;同步放化疗 vs 单纯放疗:P=0.008),诱导化疗+放疗组未见显著改善(P=0.306)。
  • ACE-27评分为0、1、2分时,放化疗 vs 单纯放疗的5年总生存分别为76.0% vs 70.0%(P=0.014)、80.5% vs 68.2%(P=0.150)、58.5% vs 62.2%(P=0.490)。

关键数值与推荐

  • 预后良好组:EBV DNA≤4000 copies/mL且T1-2。
  • 预后不良组:EBV DNA≤4000 copies/mL且T3-4,以及EBV DNA>4000 copies/mL且任何T。
  • 作者提出的化疗获益筛选界值:EBV DNA<4000 copies/ml且T3-4、EBV DNA≥4000 copies/ml且任何T,但不适用于>70岁且ACE-27评分>1者。

临床怎么用

  • 作者认为EBV DNA<4000 copies/ml且T3-4、EBV DNA≥4000 copies/ml且任何T可能是老年鼻咽癌患者化疗获益的简单筛选界值,但不适用于>70岁且ACE-27评分>1者。
  • 作者认为诱导化疗+同步放化疗和同步放化疗是有效的化疗形式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Using real-world evidence, this study aimed to identify elderly nasopharyngeal carcinoma (NPC) patients who would benefit from chemotherapy. METHODS AND MATERIALS: 1714 elderly NPC patients between April 2007 and December 2017 were identified. Recursive partitioning analysis (RPA) was used to generate risk-stratified outcomes. Prognostic factors were performed for individual comparisons of different risk groups to assess chemotherapy benefits. RESULTS: The median follow-up was 59.3 (0.39-170.09) months. Epstein Barr virus (EBV) DNA and T stage were included in the RPA-generated risk stratification, categorizing patients into a good-prognosis group (EBV DNA ≤ 4000 copies/mL & T1-2), and a poor-prognosis group (EBV DNA ≤ 4000 copies/mL & T3-4 and EBV DNA > 4000 copies/mL & any T). Overall survival (OS) was significantly higher in the good-prognosis group compared with the training set (HR = 0.309, 95% CI 0.184-0.517; P < 0.001), and validated in the testing set (HR = 0.276, 95% CI 0.113-0.670; P = 0.002). In the poor-prognosis group, a significantly improved OS for chemoradiotherapy (CRT) compared with RT alone was observed (HR = 0.70, 95% CI 0.55-0.88; P = 0.003). Patients who received induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) and CCRT had a significantly improved OS compared with RT alone (IC + CCRT vs. RT alone: P = 0.002; CCRT vs. RT alone: P = 0.008) but not in the IC + RT group (P = 0.306). The 5-year OS for CRT versus RT-alone with ACE-27 scores of 0, 1 and 2 were 76.0% versus 70.0% (P = 0.014), 80.5% versus 68.2% (P = 0.150) and 58.5% versus 62.2% (P = 0.490), respectively; for those aged 60-64, 65-70 and ≥ 70 years old they were 80.9% versus 75.9% (P = 0.068), 73.3% versus 63.4% (P = 0.270) and 64.8% versus 67.1% (P = 0.820), respectively. CONCLUSIONS: For elderly NPC patients a simple screening cutoff for chemotherapy beneficiaries might be EBV DNA < 4000 copies/ml & T3-4 and EBV DNA ≥ 4000 copies/ml & any T, but not for those > 70 years old and with an ACE-27 score > 1. IC + CCRT and CCRT were effective forms of chemotherapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Yang KB, Huang Y, et al. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study. Radiat Oncol. 2022. PMID: 35941674. doi:10.1186/s13014-022-02095-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。